SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): July 1, 2020 (June 29, 2020)
PLURISTEM THERAPEUTICS INC.
(Exact Name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction
|(Commission File Number)||
|MATAM Advanced Technology Park|
|Building No. 5|
|(Address of Principal Executive Offices)||(Zip Code)|
011 972 74 710 7171
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|☐||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|☐||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|☐||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|☐||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol(s)||Name of each exchange on which registered|
|Common Stock, par value $0.00001 per share||PSTI||The Nasdaq Capital Market|
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|Item 5.02.||Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.|
On June 29, 2020, Pluristem Therapeutics Inc., or the Company, held its 2020 Annual Meeting of Stockholders, or the 2020 Annual Meeting. As a result of the voting outcome from the 2020 Annual Meeting, on June 30, 2020, each of Israel Ben-Yoram and Nachum Rosman notified the Company of their decision to resign as members of the Board of Directors, or the Board, effective immediately. At the time of their respective resignations, Mr. Ben-Yoram was an independent director and member of the Audit Committee and Compensation Committee of the Board and Mr. Rosman was an independent director and member of the Audit Committee, Compensation Committee and Nominating Committee of the Board. Messers. Ben-Yoram and Rosman’s resignations as members of the Board also constitute their resignations as members of each of these committees. Messers. Ben-Yoram and Rosman’s resignations were not because of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
On July 1, 2020, the Board determined that Ms. Moria Kwiat is deemed to be an independent board member. In addition, the Board appointed Ms. Kwiat and Isaac Braun to serve on the Audit Committee, determined that Mr. Doron Shorrer is an Audit Committee financial expert and appointed Mr. Braun to serve on the Compensation Committee.
|Item 5.07.||Submission of Matters to a Vote of Security Holders.|
On June 29, 2020, the Company held its 2020 Annual Meeting. The results of stockholder voting at the 2020 Annual Meeting are set forth below:
Proposal No. 1 — Election of Directors
The stockholders elected the following individuals as directors of the Company to hold office until the next annual meeting of shareholders and until their successors shall have been duly elected and qualified.
|Director Name||For||Against||Abstain||Broker Non-Votes|
Proposal No. 2 — Ratification of the selection of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as independent registered public accounting firm of the Company for the fiscal year ending June 30, 2020.
Proposal No. 3 — Approval of an amendment to the Articles of Incorporation of the Company to increase the number of authorized shares of common stock.
The results reported above are final voting results.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|PLURISTEM THERAPEUTICS INC.|
|Date: July 1, 2020||By:||/s/ Chen Franco-Yehuda|
|Title:||Chief Financial Officer|